Vancouver, BC, April 29, 2008--(T-Net)--Angiotech Pharmaceuticals (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced its financial results for the first quarter ended March 31, 2008.
"Our various initiatives delivered results during the first quarter," said Dr. William Hunter, President and CEO of Angiotech. "Product sales grew across all of our business lines, our promoted brands had strong revenues across the board, sales for our Quill SRS product, which continues to generate excitement in the physician community, were in line with our expectations, and our 5-FU CVC product was approved by the FDA ahead of our expected timeline."
"We believe our first quarter financial results represent a turning point for Angiotech," said Thomas Bailey, Chief Financial Officer of Angiotech.
Read More
Monday, May 26, 2008
Subscribe to:
Posts (Atom)